Related references
Note: Only part of the references are listed.Pharmacokinetics, tissue distribution, and antitumor activity of a novel compound, NY-2, in non-small cell lung cancer
Yingshi Zhang et al.
FRONTIERS IN PHARMACOLOGY (2023)
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Aaron C. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents
Raquel Navarro et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2022)
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Bob T. Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Alissa J. Cooper et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
A Novel Small-Molecule Inhibitor of SREBP-1 Based on Natural Product Monomers Upregulates the Sensitivity of Lung Squamous Cell Carcinoma Cells to Antitumor Drugs
De-Bin Ma et al.
FRONTIERS IN PHARMACOLOGY (2022)
Therapeutic regulation of autophagy in hepatic metabolism
Katherine Byrnes et al.
ACTA PHARMACEUTICA SINICA B (2022)
A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma
Da Mao et al.
FRONTIERS IN PHARMACOLOGY (2022)
An ADAM17-Neutralizing Antibody Reduces Inflammation and Mortality While Increasing Viral Burden in a COVID-19 Mouse Model
Jodi F. Hedges et al.
FRONTIERS IN IMMUNOLOGY (2022)
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Hamid Mithoowani et al.
CURRENT ONCOLOGY (2022)
Notch signaling pathway: architecture, disease, and therapeutics
Binghan Zhou et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Structural basis of γ-secretase inhibition and modulation by small molecule drugs
Guanghui Yang et al.
CELL (2021)
Disruption of the endopeptidase ADAM10-Notch signaling axis leads to skin dysbiosis and innate lymphoid cell-mediated hair follicle destruction
Keiko Sakamoto et al.
IMMUNITY (2021)
Biophysics of Notch Signaling
David Sprinzak et al.
ANNUAL REVIEW OF BIOPHYSICS, VOL 50, 2021 (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients
Ji-Hai Wang et al.
PHARMACOLOGICAL RESEARCH (2021)
γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment
Hui Jia et al.
LIFE SCIENCES (2021)
Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution
Matteo Calligaris et al.
MOLECULES (2021)
Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma
Wei Zhou et al.
PHARMACOLOGICAL RESEARCH (2021)
Cimigenoside functions as a novel γ-secretase inhibitor and inhibits the proliferation or metastasis of human breast cancer cells by γ-secretase/Notch axis
Hui Jia et al.
PHARMACOLOGICAL RESEARCH (2021)
Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
Junyu Long et al.
BMC MEDICINE (2021)
Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma
Yamin Jie et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Phthalates promote the invasion of hepatocellular carcinoma cells by enhancing the interaction between Pregnane X receptor and E26 transformation specific sequence 1
Yabing Du et al.
PHARMACOLOGICAL RESEARCH (2021)
The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
Xiaohua Li et al.
FRONTIERS IN IMMUNOLOGY (2021)
MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor
Qiyu Jiang et al.
FRONTIERS IN ONCOLOGY (2021)
Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo
Hong-Yuan Lu et al.
LIFE SCIENCES (2020)
Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling
Sampath K. Loganathan et al.
SCIENCE (2020)
Notch Transduction in Non-Small Cell Lung Cancer
Amnah Sharif et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
ADAM10mediates ectopic proximal tubule development and renal fibrosis through Notch signalling
Bingjue Li et al.
JOURNAL OF PATHOLOGY (2020)
Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents
Ying-Qi Feng et al.
ONCOTARGETS AND THERAPY (2020)
DNA methyltransferase mediates the hypermethylation of the microRNA 34a promoter and enhances the resistance of patient-derived pancreatic cancer cells to molecular targeting agents
Yan Ma et al.
PHARMACOLOGICAL RESEARCH (2020)
FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis
Hua Yang et al.
CELL DEATH & DISEASE (2020)
Daurinoline suppressed the migration and invasion of chemo-resistant human non-small cell lung cancer cells by reversing EMT and Notch-1 and sensitized the cells to Taxol
Dan-Dan Li et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
ADAM17: An Emerging Therapeutic Target for Lung Cancer
Mohamed Saad et al.
CANCERS (2019)
Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo
Hong-Yuan Lu et al.
PHARMACOLOGICAL RESEARCH (2019)
Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI-Mediated Anticancer Activity in NSCLC
Zheng Yang et al.
TRANSLATIONAL ONCOLOGY (2019)
MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents
Bin Yang et al.
CELL DEATH & DISEASE (2019)
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Isabelle Solassol et al.
BIOMOLECULES (2019)
Structural basis of Notch recognition by human γ-secretase
Guanghui Yang et al.
NATURE (2019)
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Lais Osmani et al.
SEMINARS IN CANCER BIOLOGY (2018)
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells
Yingshi Zhang et al.
CELL DEATH & DISEASE (2018)
Notch Signaling in the Tumor Microenvironment
Olivier Meurette et al.
CANCER CELL (2018)
A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo
Dan-Dan Li et al.
CELL PROLIFERATION (2018)
Specific inhibition of ADAM17/TACE promotes neurogenesis in the injured motor cortex
Noelia Geribaldi-Doldan et al.
CELL DEATH & DISEASE (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Dysregulation of the ADAM17/Notch signalling pathways in endometriosis: from oxidative stress to fibrosis
Inaki Gonzalez-Foruria et al.
MOLECULAR HUMAN REPRODUCTION (2017)
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2017)
Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal
Li An et al.
PHARMACOLOGICAL RESEARCH (2017)
Progressive and Prognosis Value of Notch Receptors and Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Yingshi Zhang et al.
SCIENTIFIC REPORTS (2017)
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents
Hui Jia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2016)
Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer
Ashish Sharma et al.
CLINICAL CANCER RESEARCH (2016)
Rhamnetin and Cirsiliol Induce Radiosensitization and Inhibition of Epithelial-Mesenchymal Transition (EMT) by miR-34a-mediated Suppression of Notch-1 Expression in Non-small Cell Lung Cancer Cell Lines
JiHoon Kang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival
Shuang-Shuang Ni et al.
TUMOR BIOLOGY (2013)
ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer
Anja Baumgart et al.
CANCER RESEARCH (2010)
Identification of potent and selective TACE inhibitors via the S1 pocket
Jeffrey S. Condon et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Identification and characterization of 4-[[4-(2-butynyloxy) phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)-thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-α-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis
YH Zhang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Tumor necrosis factor-α-converting enzyme (ADAM17) mediates GPIbα shedding from platelets in vitro and in vivo
W Bergmeier et al.
CIRCULATION RESEARCH (2004)
Share Paper
